Latest News

Spain Services Growth Remains Strong In June

Wednesday July 4 th 2018

(RTTNews) – Spain’s services sector growth remained robust in June, despite rates of expansion in activity and new business easing slightly from May, survey data from IHS Markit showed Wednesday.

The services Purchasing Managers’ Index dropped 55.4 in June from 56.4 in May. However, any reading above 50 indicates expansion in the sector.

The survey revealed that the latest rise in activity reflected an improving economic climate.

New orders rose sharply but at a weaker pace in June. The rate of job creation remained elevated in June, posting broadly in line with that seen in May and one of the fastest since early-2007.

On the price front, input price inflation accelerated to the sharpest level since September 2008, driven by increased costs for fuel and staff. Selling price inflation also quickened from May.

“While the sister manufacturing PMI survey has shown growth moderating since the start of the year, the service sector has been able to largely maintain growth momentum,” Andrew Harker, Associate Director at IHS Markit, said.

“This should help lead to another solid rise in GDP during the second quarter of 2018.”

Global Feed Phosphates Industry 2018-2027

DUBLIN, July 4, 2018 /PRNewswire/ —

The “Global Feed Phosphates Market Analysis Trends – Industry Forecast to 2027″ report has been added to ResearchAndMarkets.com’s offering.

The Global Feed Phosphates Market is poised to grow strong during the forecast period 2017 to 2027.

Some of the prominent trends that the market is witnessing include increasing consumption of meat dairy products and high threat of diseases in livestock.

Based on Type, the market is categorized into monocalcium phosphate, defluorinated phosphate, tricalcium phosphate, tricalcium phosphate, mono-dicalcium phosphate and other types.

Depending on Form the market is segregated into granule and powder.

On the basis of Livestock the market is segmented into ruminants, aquaculture, poultry, swine and other livestocks.

Based on Disease Indication the market is segmented into cardiovascular disorders, immunological disorders, cancer, neurological disorders and other diseases.

Report Highlights

  • The report provides a detailed analysis on current and future market trends to identify the investment opportunities
  • Market forecasts till 2027, using estimated market values as the base numbers
  • Key market trends across the business segments, Regions and Countries
  • Key developments and strategies observed in the market
  • Market Dynamics such as Drivers, Restraints, Opportunities and other trends
  • In-depth company profiles of key players and upcoming prominent players
  • Growth prospects among the emerging nations through 2027
  • Market opportunities and recommendations for new investments

Key Topics Covered

1 Market Outline
1.1 Research Methodology
1.1.1 Research Approach Sources
1.2 Market Trends
1.3 Regulatory Factors
1.4 Strategic Benchmarking
1.5 Opportunity Analysis

2 Executive Summary

3 Market Overview
3.1 Current Trends
3.1.1 Increasing Consumption of Meat and Dairy Products
3.1.2 High Threat of Diseases in Livestock
3.1.3 Industrialization of the Meat Processing Industry
3.1.4 Growth Opportunities/Investment Opportunities
3.2 Drivers
3.3 Constraints
3.4 Industry Attractiveness
3.4.1 Bargaining power of suppliers
3.4.2 Bargaining power of buyers
3.4.3 Threat of substitutes
3.4.4 Threat of new entrants
3.4.5 Competitive rivalry

4 Feed Phosphates Market, By Type
4.1 Monocalcium Phosphate
4.1.1 Monocalcium Phosphate Market Forecast to 2027 (US$ MN)
4.2 Defluorinated Phosphate
4.2.1 Defluorinated Phosphate Market Forecast to 2027 (US$ MN)
4.3 Tricalcium Phosphate
4.3.1 Tricalcium Phosphate Market Forecast to 2027 (US$ MN)
4.4 Dicalcium Phosphate
4.4.1 Dicalcium Phosphate Market Forecast to 2027 (US$ MN)
4.5 Mono-Dicalcium Phosphate
4.5.1 Mono-Dicalcium Phosphate Market Forecast to 2027 (US$ MN)
4.6 Other Types
4.6.1 Other Types Market Forecast to 2027 (US$ MN)

5 Feed Phosphates Market, By Form
5.1 Granule
5.1.1 Granule Market Forecast to 2027 (US$ MN)
5.2 Powder
5.2.1 Powder Market Forecast to 2027 (US$ MN)

6 Feed Phosphates Market, By Livestock
6.1 Ruminants
6.1.1 Ruminants Market Forecast to 2027 (US$ MN)
6.2 Aquaculture
6.2.1 Aquaculture Market Forecast to 2027 (US$ MN)
6.3 Poultry
6.3.1 Poultry Market Forecast to 2027 (US$ MN)
6.4 Swine
6.4.1 Swine Market Forecast to 2027 (US$ MN)
6.5 Other Livestocks
6.5.1 Other Livestocks Market Forecast to 2027 (US$ MN)

7 Feed Phosphates Market, By Disease Indication
7.1 Cardiovascular Disorders
7.1.1 Cardiovascular Disorders Market Forecast to 2027 (US$ MN)
7.2 Immunological Disorders
7.2.1 Immunological Disorders Market Forecast to 2027 (US$ MN)
7.3 Cancer
7.3.1 Cancer Market Forecast to 2027 (US$ MN)
7.4 Neurological Disorders
7.4.1 Neurological Disorders Market Forecast to 2027 (US$ MN)
7.5 Other Diseases
7.5.1 Other Diseases Market Forecast to 2027 (US$ MN)

8 Feed Phosphates Market, By Geography
8.1 North America
8.1.1 North America Market Forecast by Countries to 2027 (US$ MN)
8.1.1.1 US
8.1.1.2 Canada
8.1.1.3 Mexico
8.2 Europe
8.2.1 Europe Market Forecast by Countries to 2027 (US$ MN)
8.2.1.1 Germany
8.2.1.2 UK
8.2.1.3 Italy
8.2.1.4 France
8.2.1.5 Spain
8.2.1.6 Rest of Europe
8.3 Asia Pacific
8.3.1 Asia Pacific Market Forecast by Countries to 2027 (US$ MN)
8.3.1.1 China
8.3.1.2 Japan
8.3.1.3 India
8.3.1.4 Australia
8.3.1.5 New Zealand
8.3.1.6 Rest of Asia Pacific
8.4 Middle East
8.4.1 Middle East Market Forecast by Countries to 2027 (US$ MN)
8.4.1.1 Saudi Arabia
8.4.1.2 UAE
8.4.1.3 Rest of Middle East
8.5 Latin America
8.5.1 Latin America Market Forecast by Countries to 2027 (US$ MN)
8.5.1.1 Argentina
8.5.1.2 Brazil
8.5.1.3 Rest of Latin America
8.6 Rest of the World (RoW)
8.6.1 RoW Market Forecast by Countries to 2027 (US$ MN)
8.6.1.1 South Africa
8.6.1.2 Others

9 Key Player Activities
9.1 Mergers Acquisitions
9.2 Partnerships, Joint Venture’s, Collaborations and Agreements
9.3 Product Launch Expansions
9.4 Other Activities

10 Leading Companies
10.1 Yara International ASA
10.2 Phosagro
10.3 The Mosaic Company
10.4 OCP Group
10.5 Quimpac S.A.
10.6 Sichuan Lomon Corporation
10.7 Rotem Turkey
10.8 Eurochem Group AG
10.9 Fosfitalia Group
10.10 J.R. Simplot Company
10.11 Ecophos Group
10.12 Sinochem Yunlong Co., Ltd.
10.13 Nutrien Ltd.
10.14 Wengfu Group
10.15 Phosphea

For more information about this report visit https://www.researchandmarkets.com/research/2fnr43/global_feed?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/global-feed-phosphates-industry-2018-2027—growth-prospects-and-market-opportunities-300675987.html

SOURCE Research and Markets

Facebook slides on news of SEC, FBI, FTC probes

Tuesday July 3 rd 2018

<!– –>



Mark Zuckerberg vocalization during a Viva Technology discussion in Paris, France, on Thursday, May 24, 2018.

Facebook batch slipped roughly 1.5 percent after-hours on Monday after The Washington Post reported that sovereign investigators are broadening their inquiries into a company’s information pity practices.

The FBI, SEC, and FTC have all assimilated a Justice Department in a review of Facebook following revelations of a information pity with consulting association Cambridge Analytica, people informed with a conditions told The Post.

Earlier this year, a Justice Department began questioning Facebook’s information pity practices after several press reports suggested that Cambridge Analytica harvested Facebook form information from tens of million users but their demonstrate consent. The broadening of a review to embody a FBI, SEC, and FTC will stress either Facebook done sufficient disclosures to a users and a investors.

“We are auxiliary with officials in a US, UK and beyond,” a Facebook orator pronounced in a statement. “We’ve supposing open testimony, answered questions, and affianced to continue a assistance as their work continues.”

You can review a rest of The Washington Post story here.





Playing

Share this video…

Watch Next…

Motif Bio Announces Resignation of Robert Bertoldi from Board of Directors

NEW YORK, July 03, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Robert Bertoldi has informed the Company of his decision to resign from the Board of Directors, effective July 16, 2018.

Graham Lumsden, Chief Executive Officer of Motif Bio, said: “On behalf of the Board, we are grateful to Bob for his dedication and service to the company since its inception.  We have appreciated his insight and wish him future success.�

For further information please contact:

Note to Editors:

About Motif Bio

Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for hospitalised patients and designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria, including MRSA. The Company’s lead product candidate is iclaprim. Following positive results from two Phase 3 trials (REVIVE-1 and REVIVE-2), an NDA has been submitted to the U.S. FDA for the treatment of acute bacterial skin and skin structure infections (ABSSSI). More than 3.6 million patients with ABSSSI are hospitalised annually in the U.S. It is estimated that up to 26% of hospitalized ABSSSI patients have renal impairment. The Company believes, based on the data from the Phase 3 REVIVE studies, that iclaprim may be suitable for first-line empiric therapy in ABSSSI patients, including  those with renal impairment, with or without diabetes.

The Company also plans to develop iclaprim for hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), as there is a high unmet need for new therapies in this indication.  A Phase 2 trial in patients with HABP has been successfully completed and a Phase 3 trial is being planned. Additionally, iclaprim has been granted orphan drug designation by the FDA for the treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis and is in preclinical development for this indication.

Iclaprim has received Qualified Infectious Disease Product (QIDP) designation from the FDA together with Fast Track status. Upon acceptance by the FDA of an NDA, iclaprim will receive Priority Review status and, if approved as a New Chemical Entity, will be eligible for 10 years of market exclusivity in the U.S. from the date of first approval, under the Generating Antibiotic Incentives Now Act (the GAIN Act). In Europe, 10 years of market exclusivity is anticipated.

Forward-Looking Statements

This press release contains forward-looking statements. Words such as “expect,� “believe,� “intend,� “plan,� “continue,� “may,� “will,� “anticipate,� and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Motif Bio’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Motif Bio believes that these factors include, but are not limited to, (i) the timing, progress and the results of clinical trials for Motif Bio’s product candidates, (ii) the timing, scope or likelihood of regulatory filings and approvals for Motif Bio’s product candidates, (iii) Motif Bio’s ability to successfully commercialise its product candidates, (iv) Motif Bio’s ability to effectively market any product candidates that receive regulatory approval, (v) Motif Bio’s commercialisation, marketing and manufacturing capabilities and strategy, (vi) Motif Bio’s expectation regarding the safety and efficacy of its product candidates, (vii) the potential clinical utility and benefits of Motif Bio’s product candidates, (viii) Motif Bio’s ability to advance its product candidates through various stages of development, especially through pivotal safety and efficacy trials, (ix) Motif Bio’s estimates regarding the potential market opportunity for its product candidates, and (x) the factors discussed in the section entitled “Risk Factors� in Motif Bio’s Annual Report on Form 20-F filed with the SEC on April 10, 2018, which is available on the SEC’s web site, www.sec.gov. Motif Bio undertakes no obligation to update or revise any forward-looking statements.

Aegon and Santander to expand successful partnership in Spain

Aegon today announces that it has signed an agreement to expand its
successful partnership with Banco Santander in Spain. The expansion
covers term life and selected lines of non-life insurance following
Banco Santander’s acquisition of the Banco Popular franchise in 2017.

“I am delighted to announce an expansion of the existing relationship
with Banco Santander, which will give us access to an additional client
base of four million customers in Spain�, said Alex Wynaendts, CEO of
Aegon. “From the very start of the partnership, Santander and AEGON have
created a successful collaboration in Spain, generating healthy returns
and remittances to the group�.

The joint venture with Banco Santander in Spain has been commercially
successful, with an average yearly growth in gross written premiums of
12% over the period 2014-2017. The new agreement with Banco Santander is
expected to lead to substantial growth going forward. Products provided
by the joint venture include term life, household, accident and health
insurance.

Aegon agreed to an upfront consideration of EUR 215 million and an
additional amount of up to EUR 75 million to be paid after 5 years,
depending on the performance of the partnership. The consideration will
be funded from holding excess cash. The final terms (including closing
and date of payment) of the transaction are subject to due diligence,
regulatory approval, several other conditions and to the process of
terminating the existing alliances of Banco Popular.

About Aegon

Aegon’s roots go back more than 170 years – to the first half of the
nineteenth century. Since then, Aegon has grown into an international
company, with businesses in more than 20 countries in the Americas,
Europe and Asia. Today, Aegon is one of the world’s leading financial
services organizations, providing life insurance, pensions and asset
management. Aegon’s purpose is to help people achieve a lifetime of
financial security. More information on aegon.com/about.

Disclaimer

Forward-looking statements

The statements contained in this document that are not historical facts
are forward-looking statements as defined in the US Private Securities
Litigation Reform Act of 1995. The following are words that identify
such forward-looking statements: aim, believe, estimate, target, intend,
may, expect, anticipate, predict, project, counting on, plan, continue,
want, forecast, goal, should, would, could, is confident, will, and
similar expressions as they relate to Aegon. These statements are not
guarantees of future performance and involve risks, uncertainties and
assumptions that are difficult to predict. Aegon undertakes no
obligation to publicly update or revise any forward-looking statements.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which merely reflect company expectations at
the time of writing. Actual results may differ materially from
expectations conveyed in forward-looking statements due to changes
caused by various risks and uncertainties. Such risks and uncertainties
include but are not limited to the following:

  • Changes in general economic conditions, particularly in the United
    States, the Netherlands and the United Kingdom;
  • Changes in the performance of financial markets, including emerging
    markets, such as with regard to:

– The frequency and severity of defaults by issuers in Aegon’s fixed
income investment portfolios;

– The effects of corporate bankruptcies and/or accounting restatements
on the financial markets and the resulting decline in the value of
equity and debt securities Aegon holds; and

– The effects of declining creditworthiness of certain public sector
securities and the resulting decline in the value of government exposure
that Aegon holds;

  • Changes in the performance of Aegon’s investment portfolio and decline
    in ratings of Aegon’s counterparties;
  • Consequences of an actual or potential break-up of the European
    monetary union in whole or in part;
  • Consequences of the anticipated exit of the United Kingdom from the
    European Union and potential consequences of other European Union
    countries leaving the European Union;
  • The frequency and severity of insured loss events;
  • Changes affecting longevity, mortality, morbidity, persistence and
    other factors that may impact the profitability of Aegon’s insurance
    products;
  • Reinsurers to whom Aegon has ceded significant underwriting risks may
    fail to meet their obligations;
  • Changes affecting interest rate levels and continuing low or rapidly
    changing interest rate levels;
  • Changes affecting currency exchange rates, in particular the EUR/USD
    and EUR/GBP exchange rates;
  • Changes in the availability of, and costs associated with, liquidity
    sources such as bank and capital markets funding, as well as
    conditions in the credit markets in general such as changes in
    borrower and counterparty creditworthiness;
  • Increasing levels of competition in the United States, the
    Netherlands, the United Kingdom and emerging markets;
  • Changes in laws and regulations, particularly those affecting Aegon’s
    operations’ ability to hire and retain key personnel, taxation of
    Aegon companies, the products Aegon sells, and the attractiveness of
    certain products to its consumers;
  • Regulatory changes relating to the pensions, investment, and insurance
    industries in the jurisdictions in which Aegon operates;
  • Standard setting initiatives of supranational standard setting bodies
    such as the Financial Stability Board and the International
    Association of Insurance Supervisors or changes to such standards that
    may have an impact on regional (such as EU), national or US federal or
    state level financial regulation or the application thereof to Aegon,
    including the designation of Aegon by the Financial Stability Board as
    a Global Systemically Important Insurer (G-SII);
  • Changes in customer behavior and public opinion in general related to,
    among other things, the type of products Aegon sells, including legal,
    regulatory or commercial necessity to meet changing customer
    expectations;
  • Acts of God, acts of terrorism, acts of war and pandemics;
  • Changes in the policies of central banks and/or governments;
  • Lowering of one or more of Aegon’s debt ratings issued by recognized
    rating organizations and the adverse impact such action may have on
    Aegon’s ability to raise capital and on its liquidity and financial
    condition;
  • Lowering of one or more of insurer financial strength ratings of
    Aegon’s insurance subsidiaries and the adverse impact such action may
    have on the premium writings, policy retention, profitability and
    liquidity of its insurance subsidiaries;
  • The effect of the European Union’s Solvency II requirements and other
    regulations in other jurisdictions affecting the capital Aegon is
    required to maintain;
  • Litigation or regulatory action that could require Aegon to pay
    significant damages or change the way Aegon does business or both;
  • As Aegon’s operations support complex transactions and are highly
    dependent on the proper functioning of information technology,
    operational risks such as system disruptions or failures, security or
    data privacy breaches, cyberattacks, human error, failure to safeguard
    personally identifiable information, changes in operational practices
    or inadequate controls including with respect to third parties with
    which we do business may disrupt Aegon’s business, damage its
    reputation and adversely affect its results of operations, financial
    condition and cash flows;
  • Customer responsiveness to both new products and distribution channels;
  • Competitive, legal, regulatory, or tax changes that affect
    profitability, the distribution cost of or demand for Aegon’s products;
  • Changes in accounting regulations and policies or a change by Aegon in
    applying such regulations and policies, voluntarily or otherwise,
    which may affect Aegon’s reported results, shareholders’ equity or
    regulatory capital adequacy levels;
  • Aegon’s projected results are highly sensitive to complex mathematical
    models of financial markets, mortality, longevity, and other dynamic
    systems subject to shocks and unpredictable volatility. Should
    assumptions to these models later prove incorrect, or should errors in
    those models escape the controls in place to detect them, future
    performance will vary from projected results;
  • The impact of acquisitions and divestitures, restructurings, product
    withdrawals and other unusual items, including Aegon’s ability to
    integrate acquisitions and to obtain the anticipated results and
    synergies from acquisitions;
  • Catastrophic events, either manmade or by nature, could result in
    material losses and significantly interrupt Aegon’s business; and
  • Aegon’s failure to achieve anticipated levels of earnings or
    operational efficiencies as well as other cost saving and excess cash
    and leverage ratio management initiatives.

This press release contains information that qualifies, or may qualify,
as inside information within the meaning of Article 7(1) of the EU
Market Abuse Regulation (596/2014).Further details of potential risks
and uncertainties affecting Aegon are described in its filings with the
Netherlands Authority for the Financial Markets and the US Securities
and Exchange Commission, including the Annual Report. These
forward-looking statements speak only as of the date of this document.
Except as required by any applicable law or regulation, Aegon expressly
disclaims any obligation or undertaking to release publicly any updates
or revisions to any forward-looking statements contained herein to
reflect any change in Aegon’s expectations with regard thereto or any
change in events, conditions or circumstances on which any such
statement is based.